Decorating and Loading Ghosts with Allergens for Allergen Immunotherapy

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2017 Sep 22

PMID 28934008

Citations 3

Authors

Songwe Fanuel

Saeideh Tabesh

Huda Fatima Rajani

Sahel Heidari

Esmaeil Sadroddiny

Gholam Ali Kardar

Affiliations

Soon will be listed here.

Abstract

More than 25% of the global population has IgE mediated allergic diseases. Allergen immunotherapy (AIT) is the only available form of treatment that alters the underlying mechanism of IgE-mediated allergic diseases. AIT is aimed at desensitizing allergic individuals by repeatedly administering disease-causing allergens over a long period of time. Despite its proven efficacy in numerous clinical trials, the effectiveness of AIT still suffers some drawbacks due to the quality of allergens used and in particular the unavailability of efficient allergen delivery systems. Several studies have demonstrated that bacterial ghosts (BG) systems can be used to display and deliver antigens to their targets for the management of diseases. However, there is no report documenting the use of BG systems for immunotherapy of IgE-mediated diseases so far. Thus, in this review, we intend to discuss the potentialities of BG systems for displaying and delivering allergens for future management of IgE-mediated diseases.

Citing Articles

Application of Nanoparticles for Immunotherapy of Allergic Rhinitis.

Li K, Jin J, Yang Y, Luo X, Wang Y, Xu A Int J Nanomedicine. 2024; 19:12015-12037.

PMID: 39583318 PMC: 11584337. DOI: 10.2147/IJN.S484327.

Ghosts as a Vehicle for the Delivery of DNA Vaccines Mediate Immune Responses.

Yu X, Wang L, Yang X, Zhang S, Li G, Zhang L Front Immunol. 2022; 13:849409.

PMID: 35711427 PMC: 9193971. DOI: 10.3389/fimmu.2022.849409.

Broad perspectives of allergen specific immunotherapy.

Thomas W Hum Vaccin Immunother. 2017; 13(10):2385-2389.

PMID: 28933669 PMC: 5647984. DOI: 10.1080/21645515.2017.1374522.

References

Pauli G, Larsen T, Rak S, Horak F, Pastorello E, Valenta R . Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2008; 122(5):951-60. DOI: 10.1016/j.jaci.2008.09.017. View

Witte A, Wanner G, Sulzner M, Lubitz W . Dynamics of PhiX174 protein E-mediated lysis of Escherichia coli. Arch Microbiol. 1992; 157(4):381-8. DOI: 10.1007/BF00248685. View

Curin M, Reininger R, Swoboda I, Focke M, Valenta R, Spitzauer S . Skin prick test extracts for dog allergy diagnosis show considerable variations regarding the content of major and minor dog allergens. Int Arch Allergy Immunol. 2010; 154(3):258-63. DOI: 10.1159/000321113. View

Choi S, Nam Y, Kim K . Novel expression system for combined vaccine production in Edwardsiella tarda ghost and cadaver cells. Mol Biotechnol. 2010; 46(2):127-33. DOI: 10.1007/s12033-010-9277-2. View

Langemann T, Mayr U, Meitz A, Lubitz W, Herwig C . Multi-parameter flow cytometry as a process analytical technology (PAT) approach for the assessment of bacterial ghost production. Appl Microbiol Biotechnol. 2015; 100(1):409-18. DOI: 10.1007/s00253-015-7089-9. View

Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O . Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol. 2005; 116(3):608-13. DOI: 10.1016/j.jaci.2005.06.004. View

Kassmannhuber J, Rauscher M, Schoner L, Witte A, Lubitz W . Functional display of ice nucleation protein InaZ on the surface of bacterial ghosts. Bioengineered. 2017; 8(5):488-500. PMC: 5639866. DOI: 10.1080/21655979.2017.1284712. View

Hess J, Gentschev I, Miko D, Welzel M, Ladel C, Goebel W . Superior efficacy of secreted over somatic antigen display in recombinant Salmonella vaccine induced protection against listeriosis. Proc Natl Acad Sci U S A. 1996; 93(4):1458-63. PMC: 1079202. DOI: 10.1073/pnas.93.4.1458. View

Lubitz W . Bacterial ghosts as carrier and targeting systems. Expert Opin Biol Ther. 2001; 1(5):765-71. DOI: 10.1517/14712598.1.5.765. View

10.

Jechlinger W, Haller C, Resch S, Hofmann A, Szostak M, Lubitz W . Comparative immunogenicity of the hepatitis B virus core 149 antigen displayed on the inner and outer membrane of bacterial ghosts. Vaccine. 2005; 23(27):3609-17. DOI: 10.1016/j.vaccine.2004.11.078. View

11.

Szostak M, Hensel A, Eko F, Klein R, Auer T, MADER H . Bacterial ghosts: non-living candidate vaccines. J Biotechnol. 1996; 44(1-3):161-70. DOI: 10.1016/0168-1656(95)00123-9. View

12.

Pawankar R, Mori S, Ozu C, Kimura S . Overview on the pathomechanisms of allergic rhinitis. Asia Pac Allergy. 2011; 1(3):157-67. PMC: 3206239. DOI: 10.5415/apallergy.2011.1.3.157. View

13.

Bohle B, Breitwieser A, Zwolfer B, Jahn-Schmid B, Sara M, Sleytr U . A novel approach to specific allergy treatment: the recombinant fusion protein of a bacterial cell surface (S-layer) protein and the major birch pollen allergen Bet v 1 (rSbsC-Bet v 1) combines reduced allergenicity with immunomodulating capacity. J Immunol. 2004; 172(11):6642-8. DOI: 10.4049/jimmunol.172.11.6642. View

14.

Blank S, Seismann H, Michel Y, McIntyre M, Cifuentes L, Braren I . Api m 10, a genuine A. mellifera venom allergen, is clinically relevant but underrepresented in therapeutic extracts. Allergy. 2011; 66(10):1322-9. DOI: 10.1111/j.1398-9995.2011.02667.x. View

15.

Durham S, Emminger W, Kapp A, Colombo G, de Monchy J, Rak S . Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol. 2010; 125(1):131-8.e1-7. DOI: 10.1016/j.jaci.2009.10.035. View

16.

Makatsori M, Pfaar O, Lleonart R, Calderon M . Recombinant allergen immunotherapy: clinical evidence of efficacy--a review. Curr Allergy Asthma Rep. 2013; 13(4):371-80. DOI: 10.1007/s11882-013-0359-7. View

17.

Bottazzi B, Doni A, Garlanda C, Mantovani A . An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu Rev Immunol. 2009; 28:157-83. DOI: 10.1146/annurev-immunol-030409-101305. View

18.

Guimaraes Junqueir de Queiros M, Oliveira Silva D, Alves R, Fukuhara Chiba H, Soares de Amaral V, de Almeida K . Mite-specific immunotherapy using allergen and/or bacterial extracts in atopic patients in Brazil. J Investig Allergol Clin Immunol. 2008; 18(2):84-92. View

19.

Pohlit H, Frey H, Saloga J . Could allergen-specific immunotherapy benefit from the use of nanocarriers?. Nanomedicine (Lond). 2016; 11(11):1329-31. DOI: 10.2217/nnm-2016-0111. View

20.

Matricardi P, Bjorksten B, Bonini S, Bousquet J, Djukanovic R, Dreborg S . Microbial products in allergy prevention and therapy. Allergy. 2003; 58(6):461-71. DOI: 10.1034/j.1398-9995.2003.00175.x. View